Tissue-Specific Genetic Control of Splicing: Implications for the Study of Complex Traits by Heinzen, Erin L et al.
Tissue-Specific Genetic Control
of Splicing: Implications
for the Study of Complex Traits
Erin L. Heinzen
1[, Dongliang Ge
1[, Kenneth D. Cronin
1, Jessica M. Maia
1, Kevin V. Shianna
1, Willow N. Gabriel
1,
Kathleen A. Welsh-Bohmer
2, Christine M. Hulette
2, Thomas N. Denny
3, David B. Goldstein
1*
1 Institute for Genome Sciences & Policy, Center for Human Genome Variation, Duke University, Durham, North Carolina, United States of America, 2 Joseph and Kathleen
Bryan Alzheimer’s Disease Research Center, Duke University, Durham, North Carolina, United States of America, 3 Human Vaccine Institute, Duke University, Durham, North
Carolina, United States of America
Numerous genome-wide screens for polymorphisms that influence gene expression have provided key insights into
the genetic control of transcription. Despite this work, the relevance of specific polymorphisms to in vivo expression
and splicing remains unclear. We carried out the first genome-wide screen, to our knowledge, for SNPs that associate
with alternative splicing and gene expression in human primary cells, evaluating 93 autopsy-collected cortical brain
tissue samples with no defined neuropsychiatric condition and 80 peripheral blood mononucleated cell samples
collected from living healthy donors. We identified 23 high confidence associations with total expression and 80 with
alternative splicing as reflected by expression levels of specific exons. Fewer than 50% of the implicated SNPs however
show effects in both tissue types, reflecting strong evidence for distinct genetic control of splicing and expression in
the two tissue types. The data generated here also suggest the possibility that splicing effects may be responsible for
up to 13 out of 84 reported genome-wide significant associations with human traits. These results emphasize the
importance of establishing a database of polymorphisms affecting splicing and expression in primary tissue types and
suggest that splicing effects may be of more phenotypic significance than overall gene expression changes.
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Introduction
The release of the HapMap data in 2003 and the availability
of immortalized cell lines from HapMap participants ini-
tiated a new era of research investigating how SNPs affect
how genes are expressed at the mRNA level. In 2005, two
landmark publications evaluated how SNPs affect overall
transcription in immortalized cell line samples collected from
unrelated individuals [1,2]. Since those initial publications,
the work has advanced with additional studies using more
sophisticated microarrays, larger more diverse sample sets,
and with studies of heritability of transcript and exon-level
expression [3–6].
The work to date however has been limited in scope, largely
focusing on the control of overall gene expression in
immortalized cells, which may not be representative of in
vivo patterns in speciﬁc cellular populations [7]. Only two
genome-wide studies have focused on human primary cells
[8,9], and most studies have considered only overall expres-
sion with no attempt to identify polymorphisms that have
their effects primarily on alternative splicing.
Here we extend the previous body of work by studying the
genetic control of both exon-level and whole-transcript level
variation in expression in two primary cell types, including
peripheral blood mononucleated cells (PBMCs) and cortical
brain tissue from a set of control individuals, combined with
parallel genome-wide genotyping of these samples. The
implementation of identical genome-wide screens in two
primary tissue types has allowed us to identify polymorphisms
with clear effects on both overall expression and splicing, and
to show that these effects are often tissue speciﬁc. We have
also established an easy-to-use database that allows users to
assess whether a given polymorphism is associated with any
local changes in expression and have shown that these data
suggest possible underlying causes of several published
disease associations.
Results/Discussion
Exon-level microarrays were used to quantify expression
levels of fully annotated coding sequences, EST-predicted
exons, and bioinformatically predicted exons across the
genome. These data allow direct inferences about expression
levels of speciﬁc exons. By averaging sets of exons it is also
possible to estimate expression levels for transcript species
(Figure 1, top panel). While the exon-level expression data do
not allow inference about the representation of speciﬁc (full)
Academic Editor: Edison Liu, Genome Institute of Singapore, Singapore
Received May 19, 2008; Accepted November 12, 2008; Published December 23,
2008
Copyright:  2008 Heinzen et al. This is an open-access article distributed under
the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author
and source are credited.
Abbreviations: eQTL, expression quantitative trait locus; LD, linkage disequili-
brium; MAF, minor allele frequency; PBMC, peripheral blood mononucleated cell;
sQTL, splicing quantitative trait locus
* To whom correspondence should be addressed. E-mail: d.goldstein@duke.edu
[ These authors contributed equally to this work.
PLoS Biology | www.plosbiology.org December 2008 | Volume 6 | Issue 12 | e1000001 2869
PLoS BIOLOGYtranscripts resulting from a given alternative splicing event,
they do reﬂect splicing events in how they inﬂuence the
proportion of transcripts with and without a given exon
(Figure 1, middle and bottom panels).
We ﬁrst used a principal component analysis to evaluate
overall variation in exon-level expression data, and found
that tissue source is the most important determinant of that
variation (Figure 2). We have therefore implemented ge-
nome-wide screens for SNPs controlling gene expression and
splicing (referred to as expression quantitative trait locus
[eQTL] and splicing quantitative trait locus [sQTL], respec-
tively) separately in the tissue types.
Our screen for (cis-acting) polymorphisms controlling
expression and splicing evaluated SNPs in or near (within
100 kb) either the target gene or exon. We limited this screen
to SNPs with a minor allele frequency (MAF) . 0.04 in our
sample sets (requiring at least six alleles to be present in the
tissue type investigated). The screen for cis-acting sites
controlling overall expression and those regulating exon
expression levels required approximately ten and 85 million
tests, respectively. On average 40 SNPs were considered for
each of the ;22,000 genes, including ;12 transcripts per
gene and ;four exons per transcript. Thus, thresholds for
study-wide signiﬁcance were 5 3 10
 9 for transcript level
associations and 6 3 10
 10 for exon-level associations. We
identiﬁed 584 study-wide signiﬁcant eQTLs meeting the MAF
requirements, but many of these were associated with one
another and therefore appeared to reﬂect the same causal
eQTL. We used stepwise regression to eliminate associated
SNPs, separately evaluating the two tissue types, and
identiﬁed 81 independent eQTLs. Signiﬁcant associations
that overlapped between the two tissue types were merged,
resulting in 77 transcript level associations. Associations were
separated into high conﬁdence (Table 1) and low conﬁdence
(Table S2), depending on whether the transcripts were core
transcripts, which indicates the highest level of conﬁdence.
For exon-level assessments 5,357 signiﬁcant associations
were identiﬁed in the two tissue types combined and 1,554
remained after removal of associated SNPs. We also removed
associations where the probeset contained the associated SNP
or a SNP in high linkage disequilibrium (LD, r
2 . 0.5), leaving
985 associations. Signiﬁcant associations that overlapped
between the two tissue types were merged, resulting in 929
unique exon-level associations. We also identiﬁed a subset of
these as high conﬁdence (see Table 2 and Table S3) on the
basis of the following criteria: (1) p , 10
 12, (2) no reported
SNPs within the regions covered by the associated probesets,
and (3) no suggested cross-hybridization of the associating
probeset.
For all high conﬁdence associations identiﬁed, we eval-
uated how often the expression effects of SNPs were observed
in the other tissue, and found that 74% of eQTLs and 51% of
sQTLs appeared to act exclusively in one tissue or the other.
These data clearly indicate a signiﬁcant role of tissue-speciﬁc
genetic regulation.
To conﬁrm the accuracy of the exon array technology, and
in particular the conclusion of tissue speciﬁcity, we selected a
subset of sQTLs to evaluate with quantitative real-time PCR
(qRT-PCR). Events were selected to replicate the detected
event as closely as possible, and also to establish that tissue
speciﬁcity was not the result of low resolution of the array
when exons are differentially expressed in a tissue type. We
found a highly signiﬁcant correlation between measurements
using both technologies (Figure 3) with an overall associated
p-value comparing the two methodologies (linear regression)
of 1310
 35. Importantly, we found clear replication of tissue
speciﬁcity.
We also evaluated our associations for overlap with
previously reported expression QTLs. We conﬁrmed associ-
ations with a previously reported eQTL in LRAP (renamed
ERAP2) [1], and also SNP regulation of RPS26 expression
[2,8]. While previous reports document an overall transcript
change [2,8,9], we identiﬁed the effects of the SNP to be
localized to speciﬁc exons in the RPS26 transcript. This
discrepancy is probably due to microarray platform differ-
ences. We also conﬁrmed in our PBMC sample set several
previously reported sQTLs established in HapMap cell lines,
including sQTLs in ULK4, PARP2, C17orf57, and others [5].
Taking the full list of high conﬁdence sQTLs we evaluated
how often LD extends into or surpasses regions known to be
important in splicing (Figure 4) [10]. We found that 78% of
study-wide signiﬁcant sQTLs, or their extended regions of
SNPs in high LD (r
2 . 0.2), were located near the exons they
regulated for at least one transcript containing the exon. The
remaining approximately 22% likely reﬂect unknown exons
not screened for in the array, and also possibly novel
regulatory regions that regulate splicing outside of these
well-documented regions.
Amongst all the study-wide signiﬁcant sQTLs, only two of
them are themselves located in a consensus splicing sequence
for the relevant exons, rs10814567 in POLRE1 and rs7770794
in PIP3-E. We note, however, that the probeset screening for
the associated exon in POLRE1 contains a SNP in perfect LD
with the consensus site SNP and therefore may be the result
of poor hybridization to the target. Given that most common
polymorphisms are now known, it is surprising that there are
so few cases where a candidate polymorphism responsible for
a splicing change is in the consensus sequence, although this
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Author Summary
Although humans have a relatively small complement of genes, the
proteins encoded by those genes and their biologic function are far
more complex. The increased complexity is achieved in part through
processes that create different messages from the same gene
sequence (alternative splicing) and that regulate the expression of
those messages in a tissue-specific fashion. These processes expand
the functional capacity of the human genome, but also can create
predisposition to disease when these processes go awry. In this
study, we investigated how single nucleotide polymorphisms
influence both overall gene expression and alternative splicing in
two important cell types (brain and blood) highly relevant to human
disease. Extensive and tissue-specific regulation of gene expression
and alternative splicing were observed in the two tissue types, and
some of these polymorphisms were shown to be connected to other
polymorphsims that have been recently implicated in human
diseases through genome-wide association studies. Most of these
connections appeared to relate to alternative splicing as opposed to
overall expression changes, suggesting that changes in splicing
patterns may be more consequential for disease than those
affecting only expression. These data emphasize the importance
of comprehensive studies into genetic regulation of gene expression
in all human tissue types in order to help understand how genetic
variation influences risk of common diseases.scarcity may be due to low primary representation of these
SNPs on the array. To further evaluate the role of poly-
morphisms in consensus sequences, we identiﬁed all known
polymorphisms in the conserved region located at the exon
boundaries of the close to 300,000 core exons measured on
the Affymetrix array (three basepairs into the exon and eight
into the intron, Ensembl database, National Center for
Biotechnology Information [NCBI] Build 36 hg18) and
assessed how these inﬂuenced the expression levels of
neighboring exons. A total of 2,078 SNPs were identiﬁed
with an MAF . 0.1, of which 1,011 were represented by a
proxy on the Illumina genotyping chip (r
2 ¼ 1 with the
splicing SNP in Centre d’Etude du Polymorphisme Humain
from Utah (CEU) HapMap samples). For both tissue types,
fewer than 7% of consensus site SNPs associated with
relevant exon expression levels (Table S4). While it is likely
that some associations are missed because of unknown exons
not included on the array, this number was surprisingly low
given the common conception that disruption of this highly
conserved region would very likely disrupt exon assembly. We
emphasize that this analysis only evaluates systematically the
effects of common SNPs in consensus regions at the exon
boundaries and note that rare variation may produce
profoundly different effects.
We also assessed transcript-level associations for proximity
of LD regions associated with the eQTL to promoter regions
(within 10 kb upstream of the transcript start) or in the
39UTR regions of transcripts, key regions involved in tran-
Figure 1. Idealized Representation of How Overall Expression and Alternative Splicing Events Are Reflected in the Exon Array Data
Top panel: In this study, all exon-level data were normalized across all exons and individuals. Transcript-level expression was reported for each transcript
interrogated on the array by averaging (PLIER method) exon expression levels for all exons contained in a transcript (annotation details can be found at
http://www.affymetrix.com). Subject 1 in this example has a higher overall transcript expression level (indicated by green line representing an average
of exons A–G within subject 1) compared to subject 2 (red line). In this example, all exons contained in the transcript were expressed at approximately
equal levels, suggesting that this transcript does not have alternative splice variants in either subject. Middle panel: An example of the detection of
alternative splicing in which multiple transcripts are produced from a single gene through unique combination of the coding regions. Exon D in subject
2 appears to be expressed at lower quantities when compared to the other exons in the transcript (exon D expression levels lie below the average
transcript line), indicating that this exon may be spliced out of the transcript in this subject (i.e., higher expression of transcript isoform II). Bottom panel:
A scenario where we cannot definitively establish the combinatorial assembly of exons using these data. In this example, subject 2 has lower expression
of both exons B and D. We cannot conclude that this subject has a higher proportion of transcript IV expressed compared to subject 1 or if transcript II
and III are expressed at higher levels. Despite this shortcoming in situations of large heterogeneity of transcript isoforms produced with multiple
alternative splicing events, these data provide a clear indicator of alternative exon composition within transcripts for a given individual. This study was
specifically focused on the cis-acting genetic regulation of overall expression and splicing. Therefore, we were interested in identifying groups of
splicing and expression patterns unique to individuals with the same genotype at certain commonly variant loci in and surrounding the transcript or
exon. In cases where the expression of multiple exons was under genetic regulation, we declared it a splicing event if ,40% of all exons contained in
the transcript were associated with high confidence with the genotype. If .40% of exons were implicated, this was considered to be an overall
expression change.
doi:10.1371/journal.pbio.1000001.g001
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Genetic Control of Splicing/Expressionscription and stability of mRNA transcripts [11]. Twenty-one
out of 23 high conﬁdence eQTLs or SNPS in the LD region (r
2
. 0.2) were found to be located in or extending beyond these
relevant regions involved in the steady state expression level
of mRNA transcripts.
One motivation for the current project is to facilitate rapid
evaluation of whether polymorphisms implicated in human
disease inﬂuence gene expression or splicing in relevant
tissue types. We have therefore established a user interface
called SNPExpress, which permits rapid interrogation of the
localized effects of common SNPs on exon and transcript
level expression (Figure 5). This resource is freely available at:
http://people.genome.duke.edu/;dg48/SNPExpress/.
As of April 2008, .60 genome-wide associations studies
were published identifying SNPs with convincing associations
to complex human traits. While the association of these SNPs
to the study phenotype is secure, how these polymorphisms
(or variants associated with them) confer their effects is
largely unknown. Of these published genome-wide associa-
tion scans, 41 papers document genome-wide signiﬁcant
ﬁndings for 50 different traits (84 variants). Interestingly,
outside of identifying nonsynonymous coding SNPs, only six
claim to have identiﬁed a functional molecular-level con-
sequence that may contribute to the phenotype, all of which
are expression changes at the mRNA transcript level [12–18].
To test the utility of the SNPExpress database, we evaluated
the 84 variants (Table S5) for localized associations within the
transcript/exon containing this SNP or transcripts/exons
within 100 kb of the SNP and determined thirteen to have
a strong (p , 1 3 10
 5) effect on an exon or transcript-level
expression level (Figure 5, top panel; Table 3). Of these,
rs11171739, associated with type 1 diabetes [12], was found
through the use of an Illumina proxy to have an association
with the exon-level expression of the RPS26 gene. In a follow-
up analysis, a SNP in LD with rs11171739 (rs2292239 r
2¼0.71
Figure 2. Principal Components Analysis of All Exon Expression Level
Data for Both Brain and PBMC Samples
The differentiated pattern of expression suggests the need for tissue
specific evaluations of alternative splicing and expression and demon-
strates the added benefit of studying genetic regulation of splicing and
expression in two unique and important cellular populations. A similar
profile was observed for the transcript level expression values in the two
tissue types suggesting the same level of tissue specificity for splicing.
doi:10.1371/journal.pbio.1000001.g002
Table 1. High-Confidence cis-Acting SNPs That Were Shown in This Study to Influence Transcript Level Expression
Tissue Type Transcript ID
a Gene Chromosome SNP Association (eQTL) MAF
b p-Value p-Value in Other
Tissue Type
c
Brain 3456313 ATP5G2 12 rs1971762 0.32 3.88 e
 17 NS
Brain 3391724 TMPRSS5 11 rs1318296 0.16 7.04 e
 11 NS
Brain 3319613 RPL27A 11 rs2073687 0.19 1.23 e
 09 0.003
Brain 2501317 LOC654433 2 rs12620738 0.5 1.92 e
 09 3.76 e
 09
Brain 3509645 SOHLH2 13 rs943895 0.47 4.45 e
 09 NS
PBMC 3382061 XRRA1 11 rs4944950 0.19 4.48 e
 25 1.91 e
 12
PBMC 3757329 JUP 17 rs11079013 0.08 4.47 e
 24 NS
PBMC 3333247 FADS2 11 rs968567 0.18 6.58 e
 22 NS
PBMC 3757399 NT5C3L 17 rs1046403 0.23 1.64 e
 20 NS
PBMC 2821347 ERAP2 5 rs2549782 0.48 7.82 e
 20 6.10 e
 15
PBMC 3960174 LGALS2 22 rs2235338 0.43 1.28 e
 15 NS
PBMC 3315549 PSMD13 11 rs7128029 0.25 1.80 e
 15 6.73 e
 06
PBMC 2502686 MARCO 2 rs4491733 0.24 1.31 e
 12 NS
PBMC 3299504 ACTA2 10 rs1926196 0.49 7.27 e
 12 NS
PBMC 3545130 VASH1 14 rs10483877 0.28 3.12 e
 11 NS
PBMC 3921391 WRB 21 rs2836999 0.33 3.90 e
 10 NS
PBMC 3337835 IGHMBP2 11 rs604524 0.28 4.51 e
 10 NS
PBMC 2351687 CHI3L2 1 rs654997 0.08 4.79 e
 10 NS
PBMC 3935486 S100B 21 rs2070435 0.39 6.26 e
 10 NS
PBMC 3318989 ZNF215 11 rs1491823 0.32 8.50 e
 10 NS
PBMC 3261923 AS3MT 10 rs9527 0.18 1.07 e
 09 0.003
PBMC 2438093 C1orf85 1 rs2274226 0.43 1.54 e
 09 NS
PBMC 2371065 LAMC1 1 rs10752893 0.4 4.63 e
 09 NS
aIdentifiers can be linked to genomic regions at https://www.affymetrix.com/site/login/login.affx.
bMAF observed in the study samples.
cThis column defines whether or not the association was observed in the other tissue type studied (brain/PBMC), and if so the uncorrected p-value is given.
ID, identifier; NS, not significant.
doi:10.1371/journal.pbio.1000001.t001
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Genetic Control of Splicing/ExpressionTable 2. High-Confidence cis-Acting SNPs That Were Shown in This Study to Influence Exon-Level Expression
Tissue
Type
Probeset
ID
a
Exon ID
a Transcript
ID
a
Exon Gene/
Transcript ID
Chromosome SNP
Association (sQTL)
MAF
b p-Value p-Value in Other
Tissue Type
c
Brain 2412599 59726 2412529 NRD1 1 rs10888734 0.19 3.01 e
 13 1.78 e
 11
Brain 2452744 84104 2452724 PM20D1 1 rs708727 0.2 1.74 e
 14 NS
Brain 2480976 102015 2480961 TACSTD1 2 rs4953495 0.23 1.16 e
 13 NS
Brain 2665484 218169 2665472 EFHB 3 rs4103004 0.11 8.08 e
 15 9.22 e
 06
Brain 2670619 221387 2670481 ULK4 3 rs1052501 0.11 1.64 e
 14 8.26 e
 14
Brain 2676700 224952 2676671 TKT 3 rs3736151 0.22 2.66 e
 17 5.35 e
 12
Brain 2895678 362200 2895650 SIRT5 6 rs2804919 0.19 8.89 e
 16 1.88 e
 13
Brain 3391746 669898 3391724 TMPRSS5 11 rs1318296 0.27 7.00 e
 12 NS
Brain 3779866 907351 3779817 CEP192 18 rs1786263 0.34 3.79 e
 12 0.014
Brain 3847876 948510 3847873 SLC25A23 19 rs173229 0.37 3.60 e
 13 NS
Brain 3872278 962393 3872274 VN1R1 19 rs11084499 0.16 7.72 e
 17 8.88 e
 08
PBMC 2395130 49060 2395123 UTS2 1 rs161811 0.43 8.60 e
 24 NS
PBMC 2395127 49059 2395123 UTS2 1 rs161811 0.05 3.34 e
 18 NS
PBMC 2395129 49059 2395123 UTS2 1 rs161811 0.46 1.10 e
 14 NS
PBMC 2395134 49062 2395123 UTS2 1 rs161811 0.46 5.66 e
 13 NS
PBMC 2492088 109042 2492064 JMJD1A 2 rs2367575 0.35 2.61 e
 30 3.48 e
 23
PBMC 2522629 128190 2522616 CFLAR 2 rs4487072 0.16 3.94 e
 12 NS
PBMC 2545738 142708 2545681 GTF3C2 2 rs4803 0.26 9.14 e
 12 0.001
PBMC 2553702 147836 2553682 C2orf63 2 rs7349405 0.36 9.96 e
 14 NS
PBMC 2553712 147841 2553682 C2orf63 2 rs4435493 0.36 8.78 e
 12 NS
PBMC 2562840 153481 2562821 AK095433 2 rs1437614 0.04 8.61 e
 12 3.72 e
 06
PBMC 2845747 331076 2845699 SLC12A7 5 rs4580814 0.26 1.04 e
 13 NS
PBMC 2845703 331042 2845699 SLC12A7 5 rs4580814 0.26 1.04 e
 13 NS
PBMC 2845743 331074 2845699 SLC12A7 5 rs4580814 0.26 4.17 e
 12 NS
PBMC 2845737 331068 2845699 SLC12A7 5 rs4580814 0.05 4.69 e
 12 NS
PBMC 2856062 337718 2856044 EMB 5 rs1039797 0.45 9.91 e
 12 NS
PBMC 2859687 339993 2859667 CENPK 5 rs380327 0.44 1.99 e
 19 NS
PBMC 2859711 340012 2859667 CENPK 5 rs6897886 0.26 2.19 e
 13 NS
PBMC 2859712 340012 2859667 CENPK 5 rs380327 0.26 2.49 e
 13 NS
PBMC 2890747 359199 2890741 SCGB3A1 5 rs2453176 0.04 1.69 e
 17 NS
PBMC 2898863 364257 2898746 LRRC16 6 rs17317669 0.36 6.86 e
 12 NS
PBMC 2952341 396999 2952323 MDGA1 6 rs6938061 0.33 1.96 e
 12 NS
PBMC 3031645 446399 3031624 TMEM176A 7 rs7806458 0.11 5.22 e
 18 NS
PBMC 3079177 476145 3079172 TMEM176B 7 rs7806458 0.12 2.44 e
 24 NS
PBMC 3079179 476147 3079172 TMEM176B 7 rs7806458 0.33 2.49 e
 24 NS
PBMC 3125968 505623 3125915 MTUS1 8 rs17125630 0.43 2.77 e
 14 NS
PBMC 3125964 505621 3125915 MTUS1 8 rs17125630 0.26 3.63 e
 13 NS
PBMC 3158566 526211 3158516 CPSF1 8 rs3817681 0.26 7.94 e
 13 0.006
PBMC 3158552 526204 3158516 CPSF1 8 rs3817681 0.37 4.73 e
 12 0.007
PBMC 3210531 557982 3210497 PRUNE2 9 rs561970 0.33 1.47 e
 14 NS
PBMC 3220415 564156 3220384 EDG2 9 rs1411424 0.26 7.65 e
 14 NS
PBMC 3220416 564156 3220384 EDG2 9 rs1411424 0.04 5.04 e
 12 NS
PBMC 3269681 594934 3269662 BCCIP 10 rs10794030 0.22 2.15 e
 14 1.11 e
 04
PBMC 3293248 609845 3293244 SAR1A 10 rs870801 0.43 1.73 e
 13 1.27 e
 08
PBMC 3299591 613763 3299585 LIPA 10 rs2243547 0.07 7.43 e
 14 NS
PBMC 3308539 619413 3308489 KIAA1598 10 rs10787735 0.28 4.21 e
 14 0.034
PBMC 3308522 619400 3308489 KIAA1598 10 rs10787735 0.33 3.66 e
 12 NS
PBMC 3449119 705224 3449068 TMTC1 12 rs4931215 0.38 1.69 e
 12 NS
PBMC 3568684 779134 3568667 MAX 14 rs1271582 0.33 6.48 e
 15 1.34 e
 04
PBMC 3629245 816715 3629243 RBPMS2 15 rs7174486 0.17 2.27 e
 20 0.008
PBMC 3633384 819218 3633347 MAN2C1 15 rs4886699 0.49 7.80 e
 13 3.21 e
 06
PBMC 3633383 819217 3633347 MAN2C1 15 rs4886699 0.49 7.86 e
 15 8.34 e
 04
PBMC 3633393 819221 3633347 MAN2C1 15 rs4886699 0.41 7.73 e
 16 8.44 e
 04
PBMC 3633379 819215 3633347 MAN2C1 15 rs4886699 0.41 2.76 e
 15 0.001
PBMC 3633376 819213 3633347 MAN2C1 15 rs4886699 0.33 2.05 e
 18 0.005
PBMC 3633387 819219 3633347 MAN2C1 15 rs8028182 0.45 4.50 e
 12 NS
PBMC 3675130 844504 3675116 TMEM8 16 rs3830160 0.45 1.61 e
 12 0.005
PBMC 3675125 844502 3675116 TMEM8 16 rs3830160 0.07 1.25 e
 13 NS
PBMC 3675121 844499 3675116 TMEM8 16 rs3830160 0.41 4.57 e
 13 NS
PBMC 3705422 862698 3705412 LOC400566 17 rs6565724 0.04 4.41 e
 12 3.19 e
 07
PBMC 3710287 865492 3710277 C17orf48 17 rs440655 0.33 3.34 e
 12 1.49 e
 06
PBMC 3724617 874037 3724591 C17orf57 17 rs2175290 0.26 4.20 e
 19 0.045
PBMC 3726602 875229 3726569 SPATA20 17 rs989128 0.38 2.22 e
 17 9.50 e
 07
PBMC 3726601 875229 3726569 SPATA20 17 rs989128 0.41 8.65 e
 18 1.42 e
 06
PBMC 3726604 875231 3726569 SPATA20 17 rs989128 0.43 1.83 e
 13 2.05 e
 05
PBMC 3726584 875222 3726569 SPATA20 17 rs989128 0.49 7.12 e
 13 3.72 e
 05
PBMC 3726597 875228 3726569 SPATA20 17 rs989128 0.33 3.49 e
 12 1.11 e
 04
PBMC 3726603 875230 3726569 SPATA20 17 rs989128 0.33 7.31 e
 15 2.30 e
 04
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type 1 diabetes [19]. Interestingly, a SNP located upstream of
both of these SNPs, rs10876864, was found in our dataset to
have the strongest association with a splicing event in RPS26.
This observation extends what was recently reported by
Schadt et al. [9] by speciﬁcally identifying RPS26 splicing as
responsible for the expression association with the implicated
polymorphism in type 1 diabetes. More generally, however,
these results illustrate the exceptional difﬁculty of moving
from phenotypic associations to underlying biological mech-
anisms. While the strong splicing association with RPS26
makes it a convincing candidate for being responsible for the
diabetes risk, the originally reported polymorphism is located
in the ERBB3 gene, which also has been suggested as having
direct relevance in type 1 diabetes [19]. Fortunately, the
effects may in this case be resolvable because rs10876864 has
a stronger association with the splicing change than does
rs2292239. The association between these polymorphisms,
while high, is not complete and it should be possible to
resolve which SNP is the more likely causal variant by testing
whether the originally identiﬁed polymorphism has a
stronger association with type 1 diabetes than does the
polymorphism more strongly associated with the splicing
change.
This scan of genome-wide associations for effects on
expression changes also identiﬁed splicing effects of
rs6678677, a SNP originally identiﬁed as a risk factor in
rheumatoid arthritis and later a contributor to type 1
diabetes predisposition, in the PTPN22 gene [12,19–21]. We
note that the associated SNP is located directly in the region
targeted by the associated probeset, which may result in a
false positive association, however the SNP effects were not
observed in the brain tissue despite a similar expression level
in the minor allele homozygotes. Additional work is needed
to conﬁrm this association.
Other e- or sQTLs that overlapped with associations in
genome-wide association studies were found for SNPs
previously implicated in ankylosing sponylitis, asthma, celiac
disease, Crohn disease, HDL cholesterol, lupus, multiple
sclerosis rheumatoid arthritis, and type 1 diabetes. It is
unclear why the majority of the splicing/expression associa-
tions we have found are for SNPs originally implicated in
autoimmune diseases. Although this result could reﬂect a
particular importance of splicing variation in autoimmunity,
two other possibilities seem more plausible. First, the
imbalance could be the result of a methodological bias in
evaluating a tissue type clearly relevant to immune system
function (PBMCs). While brain tissue was included, little
progress has been made identifying common variants that
inﬂuence brain-speciﬁc phenotypes in genome-wide studies.
Interestingly, for each e- or sQTL the association in the
immune system relevant PBMCs in all cases was stronger
compared to that observed in the brain tissue samples (Table
3), which argues for the importance of assessing expression
and splicing effects in tissue types most relevant to the disease
under study.
The second possible explanation for the clear excess of
candidate mechanisms in the case of autoimmune diseases is
more fundamental and relates to the growing recognition of
the importance of rare variants in common disease [22–24]. It
is generally assumed that when a common SNP is associated
with disease in a genome-wide study, that it, or some other
common variant in LD with it, is responsible for the
association. It is theoretically possible, however, that many
of the associations observed are not due to single common
variants, but rather due to a constellation of more rare
disease-causing variants that happen to occur, by chance,
more frequently along with one of the common alleles at
given SNP as opposed to the other. In such a case, the signal
of association credited to a common SNP is actually a
synthetic association resulting from the contributions of
multiple rare SNPs. In such cases a screen for a common SNP
associated with an underlying biological effect (such as
expression or splicing) is not likely to identify a causal site.
Our failure to identify any good strong candidate SNPs
controlling expression or splicing associated with disease
implicated SNPs in conditions other than autoimmune
conditions could reﬂect a difference in the importance of
Table 2. Continued.
Tissue
Type
Probeset
ID
a
Exon ID
a Transcript
ID
a
Exon Gene/
Transcript ID
Chromosome SNP
Association (sQTL)
MAF
b p-Value p-Value in Other
Tissue Type
c
PBMC 3726583 875221 3726569 SPATA20 17 rs989128 0.48 2.18 e
 12 9.73 e
 04
PBMC 3849702 949589 3849688 ZNF266 19 rs10401135 0.33 4.40 e
 16 3.64 e
 04
PBMC 3849706 949590 3849688 ZNF266 19 rs10401135 0.28 6.93 e
 12 NS
PBMC 3859901 955509 3859899 TMEM149 19 rs2871921 0.23 1.91 e
 17 2.66 e
 05
PBMC 3870669 961516 3870611 LILRB3 19 rs103294 0.49 4.89 e
 12 NS
PBMC 3894744 976106 3894727 SIRPB1 20 rs11696842 0.3 2.01 e
 25 0.005
PBMC 3894745 976106 3894727 SIRPB1 20 rs11696842 0.22 1.35 e
 20 0.03
PBMC 3894746 976107 3894727 SIRPB1 20 rs11696842 0.49 8.10 e
 22 NS
PBMC 3894747 976107 3894727 SIRPB1 20 rs11696842 0.38 2.47 e
 21 NS
PBMC 3894748 976108 3894727 SIRPB1 20 rs11696842 0.18 1.96 e
 18 NS
PBMC 3947314 1007909 3947310 C22orf32 22 rs1801311 0.38 9.72 e
 14 0.009
PBMC 3947319 1007912 3947310 C22orf32 22 rs1801311 0.34 3.05 e
 12 0.023
aIdentifiers can be linked to genomic regions at https://www.affymetrix.com/site/login/login.affx.
bMAF observed in the study samples.
cThis column defines whether or not the association was observed in the other tissue type, and if so the uncorrected p-value is given.
ID, identifier; NS, not significant.
doi:10.1371/journal.pbio.1000001.t002
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Genetic Control of Splicing/Expressioncommon variants in autoimmune disease versus other
diseases. Such a difference in the role of common variants
could be an indirect consequence of selection [25] related to
infectious disease, which has created predispositions to
autoimmune conditions. In short, outside of autoimmunity,
it is possible that many of the reported associations are
synthetic, due to multiple rare variants, and therefore the
reason that no clear expression or splicing effects have been
consistently identiﬁed at these loci.
A key challenge in human disease genomics is establishing
appropriate resources to elucidate the underlying biological
causes of polymorphisms that are associated with disease. As
demonstrated here, one key element in this effort is the
development of appropriate databases that describe the
relationship between polymorphisms and patterns of gene
Figure 3. Quantitative Real-Time PCR Confirmation of Selected Genetically Regulated Exon-Level Expression Changes in the Two Tissue Types
Three representative scenarios are presented. The top panel shows an sQTL that was present in both brain and PBMCs. The middle panel and bottom
panel show sQTLs unique to a particular tissue type, providing unequivocal evidence for tissue specific genetic regulation.
doi:10.1371/journal.pbio.1000001.g003
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Genetic Control of Splicing/Expressionexpression and splicing in multiple human primary tissue
types. As the ﬁeld transitions to the study of rare variants it
will be critical to supplement these datasets with complete
DNA resequencing data to comprehensively characterize the
full spectrum of genetic regulation of expression.
Methods
Samples. Brain tissue samples (frontal cortex) from neurologically
healthy control individuals were obtained from the National Neuro-
AIDS Tissue Consortium (NNTC), the Kathleen Price Bryan Brain
Bank (KPBBB) at Duke University, and the Oregon Brain Bank.
PBMCs from healthy living participants were purchased from
Seracare Bioservices, Cellular Technology Ltd., and also provided
by the Duke Human Vaccine Institute. All samples used in this
analysis were of European ancestry. Sample demographics are
included in Table S1. PBMCs obtained from living participants were
completely de-identiﬁed and obtained according to standards set
forth by the Duke University Institutional Review Board.
Genome-wide expression and genotyping. Affymetrix Human ST
1.0 exon arrays were used to assess exon and transcript expression
levels for all samples used in the study. Genome-wide genotyping was
performed using Illumina Human Hap550K chips. DNA and RNA
were extracted using standard Qiagen protocols. Exon array sample
preparation from total RNA was conducted based on standard
Affymetrix protocols.
Exon array data were evaluated using a series of quality control
steps deﬁned by Affymetrix for uniform hybridization intensity,
abnormal background signals, and sample outliers. The data were
normalized across all samples for a tissue type on an exon and
transcript level (four separate normalizations) per Affymetrix PLIER
protocol with a sketch-quantile normalization procedure (Affymetrix
Expression Console). This algorithm also removed undetectable
signals for the dataset using a screen for signals below a group of
antigenomic probesets. Principal component analysis (PCA) was
performed to look secondarily to identify sample outliers using
Partek Genomics Suite. Individual sample positions on top principal
component (PC) axes were exported and the effects postmortem
interval (applicable only to brain tissue analyses), age, gender, and
sample source/processing day were tested for signiﬁcance using
STATA/IC 10.0. All of the four covariates were deemed to impact
the sources of variability on both an exon and transcript level, and
were therefore included in subsequent genetic association analyses as
covariates in linear regression models. A combined normalization on
both brain tissue samples and PBMCs also was performed on both the
exon and transcript level. Principal components analyses were
performed for a combined normalization in order to demonstrate
the unique expression patterns in cortical tissue and PBMCs.
Genotyping quality was assessed using previously published
methods [13]. Brieﬂy, all SNPs that we called with a genotyping
frequency of .99% across individuals (1% rule) were included in the
analysis. All participants were also required to have a genotyping
success rate of .99% for all SNPs that passed the 1% rule. Finally,
each study-wide signiﬁcant SNP identiﬁed in this analysis was
manually evaluated in the Illumina Bead Studio ﬁles for genotyping
quality/accuracy.
Quantitative real-time PCR. Taqman-basedreal-timePCRwasused
to conﬁrm exon-level expression changes. Primers and ﬂuorescently-
labeled probes were custom designed for speciﬁc detection of exon-
level expression. The follow primers/probes were used: ULK4,
TCTCGTCCTAAAGCTTCTTCAGATT; ULK4, CTTTTCTGAG-
GATCTCTTTGAAGT; ULK4.PROBE, VIC- ATTAATTTGCTT-
GATGGGTT; SLC12A7F, ATCCTGGGCGTCATCCTCT; SLC12A7R,
CACATGGCCACGATGAGG; SLC12A7.PROBE, VIC-
CTGGTGTCCTGGAGTCCT; KLHL24F, TGGTACTAATATTGG-
GACGCAGAC; KLHL24R, CGCTTAGTTGCTGGGGAATC;
KLHL24.PROBE, VIC- TAAACAGAGAGGATCTTGGG.
FAM-labeled b-actin was used as an internal control in a multiplex
reaction. Assays were performed according to standard methods
(900-nM primer and 250-nM probe in 20-ll reaction mix, Applied
Biosystems). Fluorescence outputs were quantiﬁed in real time using
a 7900HT Fast Real Time PCR System and the data were analyzed
using SDS software v.2.2.2 (Applied Biosystems).
Statistical analyses. To screen for cis-acting genetic regulation of
splicing/expression genetic association analyses were conducted to
search for cis-acting SNPs that regulate exon-level and gene-level
expression. Speciﬁcally, associations were limited to SNPs lying in or
100 kb surrounding the region of the transcripts or exons. Linear
regression incorporating all the covariates was performed using
PLINK genome-wide association analysis toolkit (http://pngu.mgh.
harvard.edu/;purcell/plink/) [26]. To control for the possibility of
spurious associations resulting from population stratiﬁcation, we
used a modiﬁed EIGENSTRAT method [13,27]. A total of four
separate analyses were conducted, including PBMC transcript level,
PBMC exon level, brain transcript level, and brain exon level.
Thresholds for signiﬁcance at each level were calculated based on the
total number of association tests conducted within the four separate
analyses.
Initially, all SNPs were excluded from analysis if the minor allele
was not present at least six times in the sample group, translating to
an MAF cutoff of 0.04. All signiﬁcant observations that had p-values
below the threshold and that met the MAF cutoff requirement were
exported and the list was evaluated based on the following criteria: (1)
Associations that were present on the exon or transcript list that were
actually due to the opposing level were moved to the appropriate list.
Speciﬁcally, a study-wide signiﬁcant transcript level association was
reported if the p-value achieved the threshold requirements, the
affected transcript contained .2 exons, and .40% of exons
contained in a transcript were signiﬁcantly associated at exon-level
study-wide signiﬁcance level. Consistent with those rules, transcripts
containing ,2 exons associating with genotype that were study-wide
signiﬁcant and/or ,40% of exons within a transcript were affected
were removed and allowed on the exon-level list if they achieved
exon-level study-wide signiﬁcance. (2) Using stepwise linear regres-
sion (STATA/IC 10.0) associations were removed that were redundant
due to LD between SNPs. Speciﬁcally, following inclusion of the most
signiﬁcant SNP-probeset association, only SNPs that contributed
signiﬁcantly above and beyond the initial association at a p-value of
,10
 6 were considered as a separate association. (3) Finally, if the
sQTL or a SNP in LD (r
2 . 0.5) was located in a probeset for the
Figure 4. Methodological Details Evaluating the Proximity of a Detected sQTL and Its Region of LD to a Splicing Regulatory Region
Red box represents an exon whose expression is correlated with the SNP indicated by the starred red bar. All SNPs in LD with this sQTL are shown by
red bars and the height of the bar indicates the level of correlation (r
2) with the starred SNP. We assessed how often the range of LD for a given sQTL
(defined by r
2 . 0.2 with the sQTL) extended into or surpassed the splicing regulatory region. This analysis was performed by evaluating all mRNA
transcripts containing the exon regulated by the sQTL. The splicing regulatory region was defined as the genomic region from the start of the exon
located upstream of the associated exon through the stop site of the downstream exon interrogated. If the exon was part of multiple transcripts the
region including the most distal and proximal neighboring exons was defined the splicing regulatory region. If the affected exon was located at the
beginning or end of the transcript then the range was truncated at the start or stop of the transcript, respectively. Finally, if a single SNP associated with
more than one exon in a single transcript they were considered as a single entry in this analysis (i.e., sQTL LD needed only come in close proximity of
one of the affected exons to be counted as a positive entry).
doi:10.1371/journal.pbio.1000001.g004
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Genetic Control of Splicing/Expressionexon-level associations, it was excluded from any list of signiﬁcant
associations. Step 3 was not applied to transcript level associations as
these expression levels were determined over a range of exons
thereby reducing the contribution of SNPs to the expression levels.
Post hoc evaluation of the transcript level associations we identiﬁed
were manually inspected for effects of SNPs or SNPs in LD
contributing to the association by exporting the raw values,
eliminating probesets that contained a SNP, and recalculating the
expression level. None of the reported associations could be
accounted for by a SNP in a probeset measuring the transcript.
We also assessed whether associations were present in the other
sample type. The p-value for declaring an effect in the other tissue
Figure 5. SNPExpress Database
Top panel: Output showing an example of an association between rs10876864 and a splicing change in RPS26. Software permits the input of an SNP, a
gene, or a genomic region for comprehensive interrogation of associations between SNPs and exon/transcript expression levels in the regions surrounding
the SNP. The blue frame indicates the SNPs genotyped on the chip, the two lighter blue frames correspond to the log p-values for the brain and PBMC
samples, the turquoise panel contains all Ensembl transcripts, and the bottom green panel shows all of the exons/transcripts screened for on the array.
Bottom panel: This database can be applied in a SNP-centric or gene-centric approach for determining the functional and phenotypic consequences of
genetic variation on the transcriptome.
doi:10.1371/journal.pbio.1000001.g005
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Genetic Control of Splicing/Expressionwas based on a p-value cutoff of 0.05. Directionality was conﬁrmed to
be the same in the two tissue types for all overlapping associations.
All uncorrected p-values for observations in the other tissue types are
provided in the relevant tables.
See Figure 4 for methodological details regarding the screen for
proximity of sQTLs to affected exons.
To screen for effects of consensus site SNPs, we ﬁrst identiﬁed all
known SNPs located in highly conserved consensus site regions at the
exon-intron boundary including all SNPs eight basepairs into an
intron and three basepairs into an exon (Ensembl database). A total
of 2,078 common consensus site SNPs were identiﬁed, of which 1,011
had proxies (r
2 ¼ 1) with one or more SNPs on the Illumina Human
Hap550K chip allowing assessments of their effects in the present
dataset. Speciﬁcally, consensus site SNPs, or their proxies, were
assessed for signiﬁcant associations (uncorrected p , 0.05) with the
expression level of the immediate exon or exons located up- or
downstream for all transcripts containing that exon.
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Found at doi:10.1371/journal.pbio.1000001.st001 (48 KB RTF).
Table S2. Lower Conﬁdence cis-Acting SNPs That Were Shown in
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Found at doi:10.1371/journal.pbio.1000001.st002 (321 KB RTF).
Table S3. Lower Conﬁdence cis-Acting SNPs That Were Shown in
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Found at doi:10.1371/journal.pbio.1000001.st004 (285 KB RTF).
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